These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2416437)

  • 1. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
    Yamamoto M; Ujike H; Ogawa N
    Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
    Yamamoto M; Ogawa N; Ujike H
    J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
    Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy.
    Yamamoto M; Fujii S; Hatanaka Y
    Clin Neuropharmacol; 1997 Aug; 20(4):371-3. PubMed ID: 9260736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
    Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z
    Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N; Yamamoto M; Takayama H
    J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
    Kondo T
    Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
    [No Abstract]   [Full Text] [Related]  

  • 8. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
    Hoeldtke RD; Cilmi KM; Mattis-Graves K
    Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
    Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.
    Ujike H; Yamamoto M
    J Neurol Sci; 1988 Jan; 83(1):75-80. PubMed ID: 3126272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S
    Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W; Birkmayer G; Lechner H; Riederer P
    J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
    Tohgi H; Abe T; Takahashi S; Takahashi J; Ueno M; Nozaki Y
    Neurosci Lett; 1990 Aug; 116(1-2):194-7. PubMed ID: 2259448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pure akinesia presenting with antecollis].
    Ota S; Tsuchiya K
    No To Shinkei; 2005 Oct; 57(10):893-8. PubMed ID: 16277235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DL-threo-DOPS as a precursor of noradrenaline.
    Reches A; Jackson-Lewis V; Fahn S
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):202-8. PubMed ID: 3937060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of harmaline induced tremor by L-threo-3, 4-dihydroxyphenylserine, an L-norepinephrine precursor].
    Yamazaki M; Ikeda Y; Ishikawa M; Inagaki C; Tanaka C
    Nihon Yakurigaku Zasshi; 1976 Apr; 72(3):363-9. PubMed ID: 986992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in norepinephrine turnover after tyrosine or DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS).
    Gibson CJ
    Life Sci; 1988; 42(1):95-102. PubMed ID: 3121971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
    Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
    Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.